Type: Bowel or colorectal cancer
Dr Teh and her team are developing a novel approach to immunotherapy that targets a different type of white blood cell, called a regulatory T cell. This project aims to target ‘suicide genes’ to kill regulatory T cells that are surrounding the tumour.
Dr Koay and her team are developing a novel type of immunotherapy which targets a specialised subset of T-cells which possess the potential to attack cancer more effectively than existing T-cell immunotherapies.
Dr Seong Beom Ahn and team’s research aims to change CRC patient clinical management, by being able to provide certainty, clinicians will make better-informed treatment decisions.
A/Prof Griffin will conduct pre-clinical tests of a much needed new combination treatment for patients with advanced pancreatic and bowel cancers.
A/Prof Buchanan and his team will determine how the gut bacteria causes bowel cancer in younger adults by looking at samples.
Prof Molloy wants to understand why and how polyps become cancerous to reduce the incidence of bowel cancer in Australia.
Cancer Council NSW researchers have investigated if testing bowel cancer cases is a cost-effective way of revealing undiagnosed Australians with Lynch syndrome.
Professor Baker and his team aim to develop a new blood-based test to detect bowel cancer in its early stages.
Professor Maija Kohonen-Corish and her team have been developing crucial evidence on MCC protein alteration with the aim of creating new treatment targets and biomarkers for bowel cancer.
Researchers have found the incidence of bowel cancer has increased in Australians under the age of 50 but screening people 50-74 is still the best approach.